Page last updated: 2024-12-08

Phe-Tyr

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phe-Tyr : A dipeptide formed from L-phenylalanine and L-tyrosine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID515709
CHEMBL ID54572
CHEBI ID73637
SCHEMBL ID3037096

Synonyms (42)

Synonym
bdbm50049728
BSPBIO_003425
melanin synthesized from phe-tyr substrate catalyzed by tyrosinase for 40 hrs
(2s)-2-[[(2s)-2-amino-3-phenyl-propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
l-tyrosine, l-phenylalanyl-, monomer
KBIO3_002928
SPECTRUM2_001496
SPBIO_001511
SPECTRUM3_001813
NCGC00178074-01
CHEMBL54572
phenylalanyltyrosine
chebi:73637 ,
phe-tyr
(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
CCG-39203
17355-18-9
fy
f-y
l-phe-l-tyr
l-phenylalanyl-l-tyrosine
BRD-K22337096-001-01-8
AKOS022181529
FSXRLASFHBWESK-HOTGVXAUSA-N
SCHEMBL3037096
h-phe-tyr-oh
l-tyrosine, l-phenylalanyl-
DTXSID30333656
(s)-2-((s)-2-amino-3-phenylpropanamido)-3-(4-hydroxyphenyl)propanoic acid
l-phenylalanin l-tyrosin
J-010920
mfcd00037184
phenylalanine-tyrosine dipeptide
f-y dipeptide
phenylalanine tyrosine dipeptide
fy dipeptide
phenylalanyl-tyrosine
Q27142982
AT15132
BS-21728
(2s)-2-[[(2s)-2-azaniumyl-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoate
(2s)-2-[(2s)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID228722Bitter tasting threshold was expressed as log 1/T.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID233318Bitter threshold value1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1183271Inhibition of ACE (unknown origin)2014European journal of medicinal chemistry, Sep-12, Volume: 84CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.80 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index38.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]